Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 40 Records) |
| Query Trace: Lung Neoplasms and MUT[original query] |
|---|
| High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data. In vivo (Athens, Greece) 0 34 (4): 2009-2014. Santarpia Mariacarmela, Altavilla Giuseppe, Borsellino Nicolo, Girlando Andrea, Mancuso Gianfranco, Pergolizzi Stefano, Piazza Dario, Pontoriero Antonio, Valerio Maria Rosaria, Gebbia Vittor |
| Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. Journal of the National Comprehensive Cancer Network : JNCCN 2020 5 18 (5): 517-521. Chumsri Saranya, Sokol Ethan S, Soyano-Muller Aixa E, Parrondo Ricardo D, Reynolds Gina A, Nassar Aziza, Thompson E Aubr |
| The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients. Frontiers in oncology 2020 10 726. Liu Shaokun, Huang Tanxiao, Liu Ming, He Wenlong, Zhao YingShen, Yang Lizhen, Long Yingjiao, Zong Dandan, Zeng Huihui, Liu Yuanyuan, Liao Wenting, Duan Jingxian, Gong Subo, Chen Shi |
| Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Feb . Aggarwal Charu, Thompson Jeffrey C, Chien Austin L, Quinn Katie J, Hwang Wei-Ting, Black Taylor A, Yee Stephanie S, Christensen Theresa E, LaRiviere Michael J, Silva Benjamin A, Banks Kimberly C, Nagy Rebecca J, Helman Elena, Berman Abigail T, Ciunci Christine A, Singh Aditi P, Wasser Jeffrey S, Bauml Joshua M, Langer Corey J, Cohen Roger B, Carpenter Erica |
| Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). Cancer science 2020 Nov . Sakai Kazuko, Tsuboi Masahiro, Kenmotsu Hirotsugu, Yamanaka Takeharu, Takahashi Toshiaki, Goto Koichi, Daga Haruko, Ohira Tatsuo, Ueno Tsuyoshi, Aoki Tadashi, Nakagawa Kazuhiko, Yamazaki Koji, Hosomi Yukio, Kawaguchi Koji, Okumura Norihito, Takiguchi Yuichi, Sekine Akimasa, Haruki Tomohiro, Yamamoto Hiromasa, Sato Yuki, Akamatsu Hiroaki, Seto Takashi, Saeki Sho, Sugio Kenji, Nishio Makoto, Okabe Kazunori, Yamamoto Nobuyuki, Nishio Kazu |
| High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy. Cancer medicine 2021 Sep . Lyu Qiong, Zhu Weiliang, Wei Ting, Ding Weimin, Cao Manming, Wang Qiongyao, Guo Linlang, Luo Peng, Zhang Ji |
| Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Scientific reports 2021 Sep 11 (1): 18762. Morita Chie, Yoshida Tatsuya, Shirasawa Masayuki, Masuda Ken, Matsumoto Yuji, Shinno Yuki, Yagishita Shigehiro, Okuma Yusuke, Goto Yasushi, Horinouchi Hidehito, Yamamoto Noboru, Motoi Noriko, Yatabe Yasushi, Ohe Yuichi |
| Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical lung cancer 2021 Mar . Kao Chester, Powers Eric, Wu Yuan, Datto Michael B, Green Michelle F, Strickler John H, Ready Neal E, Zhang Tian, Clarke Jeffrey |
| Effect of prior therapy on tumor mutational burden in NSCLC. Translational lung cancer research 2021 4 10 (3): 1231-1238. Jonna Sushma, Vanderwalde Ari, Nieva Jorge, Poorman Kelsey Anne, Saul Michelle, von Buttlar Xinyu, Hu John Y, Liu Stephen |
| SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Apr . Alessi Joao V, Ricciuti Biagio, Spurr Liam F, Gupta Hersh, Li Yvonne Y, Glass Carolyn, Nishino Mizuki, Cherniack Andrew D, Lindsay James, Sharma Bijaya, Felt Kristen D, Rodig Scott J, Cheng Michael L, Sholl Lynette M, Awad Mark |
| Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. Translational lung cancer research 2021 3 10 (2): 826-838. Fung Andrea S, Karimi Maryam, Michiels Stefan, Seymour Lesley, Brambilla Elisabeth, Le-Chevalier Thierry, Soria Jean-Charles, Kratzke Robert, Graziano Stephen L, Devarakonda Siddhartha, Govindan Ramaswamy, Tsao Ming-Sound, Shepherd Frances |
| Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. Translational lung cancer research 2020 Dec 9 (6): 2367-2379. Xu Yanjun, Li Hui, Huang Zhiyu, Chen Kaiyan, Yu Xiaoqing, Sheng Jiamin, Zhang Han-Han, Fan Y |
| New methodology of TMB assessment from tissue and liquid biopsy in NSCLC. PloS one 2022 9 17 (9): e0275121. K?ížová ?udmila, Šafa?íková Markéta, Kalousová Marta, Pfeiferová Lucie, Kub?na Aleš Antonín, Vo?ka Michal, Ulrych Jan, Franková V?ra, Petruželka Luboš, Zima Tomáš, Feltl Dav |
| Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer. Thoracic cancer 2022 Sep . Chang Geyun, Li Weihua, Bai Hua, Duan Jianchun, Wang Zhijie, Du Xinyang, Yu Ruofei, Wang Yaxi, Wang Minghao, Zhu Yixiang, Zhang Xue, Li Li, Wan Rui, Wang J |
| Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. Journal for immunotherapy of cancer 2022 2 10 (1): . Zheng Mi |
| Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. Therapeutic advances in medical oncology 2022 12 14 17588359221141761. Lee Jii Bum, Park Hyung Soon, Choi Su Jin, Heo Seong Gu, An Ho Jung, Kim Hye Ryun, Hong Min Hee, Lim Sun Min, Chang Kyle, Quinn Katie, Odegaard Justin, Shim Byoung Yong, Cho Byoung Ch |
| Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. Frontiers in oncology 2022 11 12 972972. Sun Daqiang, Xu Meilin, Pan Chaohu, Tang Hongzhen, Wang Peng, Wu Dongfang, Luo Hait |
| Genomic landscape of lung cancer in the young. Frontiers in oncology 2022 12 910117. Ruiz Rossana, Galvez-Nino Marco, Roque Katia, Montes Jaime, Nuñez Maria, Raez Luis, Sánchez-Gambetta Sergio, Jaúregui Sandra, Viale Sandra, Smith Edward S, Pinto Joseph A, Mas Lu |
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022 Jun . Cortellini Alessio, Ricciuti Biagio, Borghaei Hossein, Naqash Abdul Rafeh, D'Alessio Antonio, Fulgenzi Claudia A M, Addeo Alfredo, Banna Giuseppe L, Pinato David Jam |
| Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. Cancers 2022 May 14 (10): . Ulivi Paola, Urbini Milena, Petracci Elisabetta, Canale Matteo, Dubini Alessandra, Bartolini Daniela, Calistri Daniele, Cravero Paola, Fonzi Eugenio, Martinelli Giovanni, Priano Ilaria, Andrikou Kalliopi, Bronte Giuseppe, Crinò Lucio, Delmonte Ange |
| Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications. Lung cancer (Amsterdam, Netherlands) 2023 8 184 107317. Huriye Seker-Cin, Timothy Kwang Yong Tay, Daniel Kazdal, Klaus Kluck, Markus Ball, Olaf Neumann, Hauke Winter, Felix Herth, Claus-Peter Heußel, Rajkumar Savai, Peter Schirmacher, Michael Thomas, Jan Budczies, Michael Allgäuer, Petros Christopoulos, Albrecht Stenzinger, Anna-Lena Volckm |
| Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population. JCO precision oncology 2023 12 7 e2300176. Micaela R Scobie, Katherine I Zhou, Sara Ahmed, Michael J Kell |
| Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. Lung cancer (Amsterdam, Netherlands) 2023 1 176 103-111. Tamiya Yutaro, Matsumoto Shingo, Zenke Yoshitaka, Yoh Kiyotaka, Ikeda Takaya, Shibata Yuji, Kato Terufumi, Nishino Kazumi, Nakamura Atsushi, Furuya Naoki, Miyamoto Shingo, Kuyama Shoichi, Nomura Shogo, Ikeno Takashi, Udagawa Hibiki, Sugiyama Eri, Nosaki Kaname, Izumi Hiroki, Sakai Tetsuya, Hashimoto Naozumi, Goto Koic |
| Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer. Translational lung cancer research 2024 9 13 (8): 1938-1949. Jinyu Long, Ying Chen, Xingguang Luo, Ruiying Rao, Chenxi Wang, Yuxin Guo, Jinhe Xu, Ping Lin, Yingfang Song, Lijuan Qu, Qinghong Liu, Jun Lu, Chengzhi Zhou, Zhengbo Song, Xiandong Lin, Hiroyuki Adachi, Jacek Jassem, Masatsugu Hamaji, Zongyang |
| Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials. Therapeutic drug monitoring 2024 6 . Wei Ren, Yingying Fang, Yujing He, Yifeng Ren, Minfang Wang, Anyi Xu, Jiale Ruan, Qinghua T |
| Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation. Journal of cancer research and clinical oncology 2024 4 150 (4): 215. Burak Bilgin, Yunus Kuralay, Sebnem Yuc |
| Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma. Investigational new drugs 2024 10 . Cong Fu, Haoran Gu, Lin Sun, Zhouyu Wang, Qin Zhang, Ningning Luo, Dongsheng Chen, Tong Zh |
| Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024 1 . Min-Min Shao, Yue-Ping Xu, Jin-Jing Zhang, Mao Mao, Meng-Chuan Wa |
| Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 1 . Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiaoxu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xueding Wang, Li Zha |
| Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer. Clinical lung cancer 2024 1 . Laurent Mathiot, Benoit Nigen, Thomas Goronflot, Sandrine Hiret, Ludovic Doucet, Elvire Pons-Tostivint, Jaafar Bennouna, Marc G Denis, Guillaume Herbreteau, Judith Raimbou |
- Page last reviewed:Feb 1, 2024
- Content source: